Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New IV drug hopes to regrow hair in severe alopecia

NCT ID NCT07533006

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 09, 2026 · Updated 8 times

Summary

This study tests a new drug called LY4005130 for adults with severe alopecia areata, a condition causing significant hair loss. About 60 participants will receive either the drug or a placebo intravenously. The goal is to see if the drug can regrow hair and to check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LY4005130 (given intravenously)
What this could lead to
If it works, this could point toward a new treatment for severe hair loss from alopecia areata.
What could go wrong
This is an early phase 2 study with only 60 people. The drug may not work better than placebo, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have severe Alopecia Areata (AA) that meets all of the following criteria: * Hair loss encompassing ≥50% and ≤90% of the scalp, as measured by Severity of Alopecia Tool (SALT) score * The duration of the current episode of severe AA is at least 6 months and does not exceed 4 years * No significant spontaneous hair regrowth in the investigator's opinion for at least 6 months * Agree not to use any AA treatments during the study Exclusion Criteria: * Primarily "diffuse" type of AA (characterized by diffuse hair shedding) * Are currently experiencing other forms of alopecia * Participants who, in the opinion of the investigator, are currently experiencing or have a history of unstable concomitant disease that requires frequent hospitalizations, and/or frequent use of systemic immunosuppressants that may interfere with participation in the study * Have received oral JAK Inhibitors in the past * Have had any major surgery within 8 weeks prior to screening or will require major surgery during the study * Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alopecia areata are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alopecia areata

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alopecia areata

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    30 sites in 7 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beijing Friendship Hospital Affiliate of Capital University

    NOT_YET_RECRUITING

    Beijing, 100050, China

  • Brigham and Women's Hospital

    RECRUITING

    Boston, Massachusetts, 02115, United States

  • Center For Dermatology Clinical Research, Inc.

    RECRUITING

    Fremont, California, 94538, United States

  • Centrum Badan Klinicznych PI-House sp. z o.o.

    RECRUITING

    Gdansk, 80-546, Poland

  • Centrum Medyczne Ginemedica

    RECRUITING

    Wroclaw, 50-414, Poland

  • Chelsea and Westminster Hospital NHS Foundation Trust

    NOT_YET_RECRUITING

    London, SW10 9NH, United Kingdom

  • Chung-Ang University Hospital

    NOT_YET_RECRUITING

    Dongjak-gu, 06973, South Korea

  • Cura Clinical Research - Santa Clarita - Kelly Johnson Parkway

    RECRUITING

    Santa Clarita, California, 91355, United States

  • Dar Clinical Research - Ottawa - Hunt Club Road

    RECRUITING

    Ottawa, K1V 1C1, Canada

  • Dermedic Jacek Zdybski

    RECRUITING

    Ostrowiec Świętokrzyski, 27-400, Poland

  • Diamond Clinic

    RECRUITING

    Krakow, 31-559, Poland

  • Erasmus Medisch Centrum

    NOT_YET_RECRUITING

    Rotterdam, 3015 GD, Netherlands

  • Health Clinical Research, LLC

    RECRUITING

    Cutler Bay, Florida, 33189, United States

  • Huashan Hospital, Fudan University

    RECRUITING

    Shanghai, 200040, China

  • Inha University Hospital

    NOT_YET_RECRUITING

    Incheon, 22332, South Korea

  • Jeonbuk National University Hospital

    NOT_YET_RECRUITING

    Jeonju, 54907, South Korea

  • Jordan Valley Dermatology & Research Center

    RECRUITING

    South Jordan, Utah, 84095, United States

  • Kelowna Health and Memory Centre

    RECRUITING

    Kelowna, V1Y 5A8, Canada

  • Kyung Hee University Hospital at Gangdong

    NOT_YET_RECRUITING

    Seoul, 05278, South Korea

  • Northridge Clinical Trials

    RECRUITING

    Northridge, California, 91325, United States

  • Revival Research Institute, LLC

    RECRUITING

    Troy, Michigan, 48084, United States

  • Royal London Hospital

    RECRUITING

    London, E1 1FR, United Kingdom

  • Ryan Clinical Research Inc.

    RECRUITING

    Newmarket, L3Y 5G8, Canada

  • SIMa Recherche

    NOT_YET_RECRUITING

    Verdun, H4G 2L8, Canada

  • Salford Royal Hospital

    NOT_YET_RECRUITING

    Salford, M6 8HD, United Kingdom

  • Seoul National University Hospital

    NOT_YET_RECRUITING

    Seoul, 03080, South Korea

  • Shanghai Skin Disease Hospital

    RECRUITING

    Shanghai, 200071, China

  • Stracskin

    RECRUITING

    Portsmouth, New Hampshire, 03801, United States

  • Texas Dermatology and Laser Specialists - San Antonio - South New Braunfels Avenue

    RECRUITING

    San Antonio, Texas, 78235, United States

  • Tianjin Medical University General Hospital

    NOT_YET_RECRUITING

    Tianjin, 300052, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.